Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients

Suzanne M Ingle, Margaret T May, M John Gill, Michael J Mugavero, Charlotte Lewden, Sophie Abgrall, Gerd Fätkenheuer, Peter Reiss, Michael S Saag, Christian Manzardo, Sophie Grabar, Mathias Bruyand, David Moore, Amanda Mocroft, Timothy R Sterling, Antonella D'Arminio Monforte, Victoria Hernando, Ramon Teira, Jodie Guest, Matthias Cavassini, Heidi M Crane, Jonathan A C Sterne, Antiretroviral Therapy Cohort Collaboration, Suzanne M Ingle, Margaret T May, M John Gill, Michael J Mugavero, Charlotte Lewden, Sophie Abgrall, Gerd Fätkenheuer, Peter Reiss, Michael S Saag, Christian Manzardo, Sophie Grabar, Mathias Bruyand, David Moore, Amanda Mocroft, Timothy R Sterling, Antonella D'Arminio Monforte, Victoria Hernando, Ramon Teira, Jodie Guest, Matthias Cavassini, Heidi M Crane, Jonathan A C Sterne, Antiretroviral Therapy Cohort Collaboration

Abstract

Background: Patterns of cause-specific mortality in individuals infected with human immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (ART).

Methods: Sixteen cohorts from Europe and North America contributed data on adult patients followed from the start of ART. Procedures for coding causes of death were standardized. Estimated hazard ratios (HRs) were adjusted for transmission risk group, sex, age, year of ART initiation, baseline CD4 count, viral load, and AIDS status, before and after the first year of ART.

Results: A total of 4237 of 65 121 (6.5%) patients died (median, 4.5 years follow-up). Rates of AIDS death decreased substantially with time since starting ART, but mortality from non-AIDS malignancy increased (rate ratio, 1.04 per year; 95% confidence interval [CI], 1.0-1.1). Higher mortality in men than women during the first year of ART was mostly due to non-AIDS malignancy and liver-related deaths. Associations with age were strongest for cardiovascular disease, heart/vascular, and malignancy deaths. Patients with presumed transmission through injection drug use had higher rates of all causes of death, particularly for liver-related causes (HRs compared with men who have sex with men: 18.1 [95% CI, 6.2-52.7] during the first year of ART and 9.1 [95% CI, 5.8-14.2] thereafter). There was a persistent role of CD4 count at baseline and at 12 months in predicting AIDS, non-AIDS infection, and non-AIDS malignancy deaths. Lack of viral suppression on ART was associated with AIDS, non-AIDS infection, and other causes of death.

Conclusions: Better understanding of patterns of and risk factors for cause-specific mortality in the ART era can aid in development of appropriate care for HIV-infected individuals and inform guidelines for risk factor management.

Keywords: HIV; antiretroviral therapy; cause-specific mortality.

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Cause-specific crude mortality rate per 1000 person-years by duration of antiretroviral therapy. Vertical axis is on log scale. Abbreviations: ART, antiretroviral therapy; CVD, cardiovascular disease.
Figure 2.
Figure 2.
Latest CD4 count before death within 6 months of death. Abbreviations: CVD, cardiovascular disease; IQR, interquartile range.

References

    1. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343:d6016.
    1. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–43.
    1. May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health. 2011;8:526–33.
    1. Leone S, Gregis G, Quinzan G, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection. 2011;39:13–20.
    1. Galli L, Spagnuolo V, Salpietro S, et al. Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. Antivir Ther. 2012;17:447–58.
    1. Aldaz P, Moreno-Iribas C, Egues N, et al. Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health. 2011;11:300.
    1. Lohse N, Gerstoft J, Kronborg G, et al. Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: a Danish population-based cohort study. J Acquir Immune Defic Syndr. 2011;57:334–9.
    1. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14:195–207.
    1. Gill MJ, May M, Lewden C, et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.
    1. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer. 2012;118:164–72.
    1. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods. AIDS. 2012;26:1311–8.
    1. Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55:1228–35.
    1. May MT, Ingle SM, Costagliola D, et al. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC) Int J Epidemiol. 2013 Advance Access published 18 April 2013. .
    1. The CoDe (“Coding of Death in HIV”) Project. Available at: . Accessed 29 May 2013.
    1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr. 2008;48:590–8.
    1. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1–19.
    1. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94:496–509.
    1. May MT, Hogg RS, Justice AC, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012;41:1807–20.
    1. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011;22:516–23.
    1. Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology. 2005;47:551–9.
    1. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev. 2010;12:183–94.
    1. Kowalska JD, Mocroft A, Ledergerber B, et al. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials. 2011;12:109–17.
    1. Kowalska JD, Reekie J, Mocroft A, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012;26:315–23.
    1. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121–30.
    1. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896–903.
    1. Horvath KJ, Eastman M, Prosser R, Goodroad B, Worthington L. Addressing smoking during medical visits: patients with human immunodeficiency virus. Am J Prev Med. 2012;43(5 suppl 3):S214–21.
    1. Schouten J, Wit FW, Stolte IG, et al. Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study. 19th International AIDS Conference,; Washington D.C.,. 2012. Abstract THAB0205.
    1. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568–77.
    1. Palella FJ, Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620–6.
    1. Moyer VA US Preventive Service Task Force. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:51–60.
    1. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27:563–72.
    1. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘non-HIV’ biomarkers. HIV Med. 2010;11:143–51.
    1. Thompson AJ, Locarnini S. Direct-acting antiviral agents for the treatment of HCV. Antivir Ther. 2012;17(6 pt B):1105–7.
    1. Munteanu DI, Rockstroh J. New agents for the treatment of hepatitis C in patients co-infected with HIV. Ther Adv Infect Dis. 2013;1:71–80.
    1. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011;12:412–21.
    1. US Department of Health and Human Services. Department of Health and Human Services; 2012. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Panel on Antiretroviral Guidelines for Adults and Adolescents. Available at: . Accessed 12 August 2013.
    1. European AIDS Clinical Society Guidelines version 6.1, November 2012. Available at: . Accessed 18 March 2013.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する